Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002024639 - CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS

Publication Number WO/2002/024639
Publication Date 28.03.2002
International Application No. PCT/US2001/016770
International Filing Date 23.05.2001
Chapter 2 Demand Filed 11.04.2002
IPC
A61K 31/5575 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
5575having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
C07C 405/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
405Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
C07D 333/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
333Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
02not condensed with other rings
04not substituted on the ring sulfur atom
26with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
28Halogen atoms
CPC
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 13/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
10of the bladder
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
A61P 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
Applicants
  • ALLERGAN, INC. [US]/[US]
Inventors
  • BURK, Robert, M.
  • HOLOBOSKI, Mark
  • POSNER, Mari, F.
Agents
  • BARAN, Robert, J.
Priority Data
09/665,79120.09.2000US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS
(FR) DÉRIVÉS DE CYCLOPENTANE UTILISÉS COMME AGENTS THÉRAPEUTIQUES
Abstract
(EN)
The present invention provides a novel compound represented by the general formula (I); wherein R is H or COR3; R1is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl; Z is CH2 or O; Y is OH, OCOR3 or =O; x is 0 or 1; and X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the goup consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
(FR)
Cette invention a trait à un nouveau composé correspondant à la formule générale (I), formule dans laquelle R représente un H ou COR3, R1 représente un H, R2, un phényle ou COR3, R2 représentant un alkyle de poids moléculaire inférieur porteur de 1 à 5 atomes de carbone et R3 représentant R2 ou un phényle, Z représente CH2 ou O, Y représente OH, COR3 ou =O, la valeur de x est égale à 0 ou à 1, X représente un n-alkyle porteur de 1 à 5 atomes de carbone, un cycloalkyle porteur de 3 à 7 atomes de carbone, un phényle, un furanyle, un thiényle ou leurs dérivés substitués, lesquels substituants peuvent être choisis dans le groupe composé par un alkyle porteur de 1 à 5 atomes de carbone, un halogène, CF3, CN, NO2, NR42, CO2R4 et OR4, R4 représente un hydrogène ou un alkyle porteur de 1 à 5 atomes de carbone, les lignes en pointillés étant indicatives de la présence ou de l'absence d'une double liaison et les lignes ondulées d'une liaison cis ou trans. Ces nouveaux composés se révèlent des plus utiles dans le traitement de la pression intra-oculaire élevée (hypertension oculaire) et du glaucome.
Latest bibliographic data on file with the International Bureau